HBM Healthcare Investments AG

HBM Healthcare Investments AG is a publicly listed Swiss investment firm specializing in the healthcare sector. The company manages a globally diversified portfolio of private and publicly traded companies in human medicine, biotechnology, medical technology, diagnostics, and related areas. Many of these companies have their lead products already available on the market or at an advanced stage of development. The portfolio companies are closely tracked and actively guided on their strategic directions. This approach makes HBM Healthcare Investments an interesting alternative to investing in big pharma and biotech companies. HBM Healthcare Investments is listed on the SIX Swiss Exchange under the ticker symbol HBMN.

The firm's investment strategy focuses on early-stage but post-seed round opportunities, primarily in the United States, Europe, China, and India. HBM Healthcare Investments has a history of significant value creation, with over 100 investments resulting in more than 60 trade sales and IPOs. Investments typically range between USD 5 million and USD 50 million. The company is managed by HBM Partners, a Swiss healthcare investor with USD 2.1 billion in assets under management. HBM Partners advises several specialized public and private equity investment funds and has a team of experienced professionals who source, analyze, and engage in private and public healthcare investments.

HBM Healthcare Investments' portfolio includes companies such as Neurelis, Swixx Biopharma, Fangzhou (Jianke.com), Acrivon Therapeutics, Viela Bio, and 1000Farmacie. These investments span various sectors within the healthcare industry, including central nervous system treatments, pharmaceutical distribution, healthcare platforms, oncology, and digital healthcare. The company's approach emphasizes adding value by leveraging its experience and worldwide industry network to support the growth of its portfolio companies through all stages of development.